A solid 2024 performance and ambitious prospects to address the challenges of agricultural and agri-food sectors
Presse release
28 January 2025
All publications
Presse release
01 April 2025
Sofiprotéol renews its commitment and confidence in the Ceva Santé Animale group
Ceva Animal Health renews its shareholding structure with all its long-standing partners and opens its capital to Mérieux Institute and ARCHIMED to accelerate its growth.
A long-standing shareholder of Ceva Santé Animale since 2014, Sofiprotéol has responded to the restructuring of the capital of the leading French animal health company and fifth largest in the world.
The investment and development subsidiary of Avril is delighted, as a loyal investor and member of the “Friends of Ceva”, to contribute to the stability of the company’s shareholding and to support its development with innovative health solutions for all livestock and pets, and in particular preventive solutions thanks to vaccines, of which CEVA is one of the world leaders.
Participants:
- Cyril Melin, Antoine Daulton et Anne-Sophie Dubourg.
About Ceva Animal Health
Ceva Animal Health (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine
such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as equipment and services to provide the best experience for our customers.
With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: “Together, beyond animal health”.
2024 turnover: €1.77 billion